

## PATENT COOPERATION TREATY

BRISBANE

From the:  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

13 JUN 2006

To:

Davies Collison Cave Level 3, 303 Coronation  
Drive Milton, Queensland 4064 Australia

**PCT**

NOTIFICATION OF TRANSMITTAL OF  
INTERNATIONAL PRELIMINARY  
REPORT ON PATENTABILITY  
(Chapter II of the Patent Cooperation Treaty)

(PCT Rule 71.1)

Date of mailing  
(day/month/year)

9 JUN 2006

Applicant's or agent's file reference  
12565110 VPA/DJH/cmb

**IMPORTANT NOTIFICATION**

International application No.  
PCT/AU2005/000187

International filing date (day/month/year)  
14 February 2005

Priority date (day/month/year)  
12 February 2004

Applicant

THE UNIVERSITY OF QUEENSLAND et al

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary report on patentability and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translations to those Offices.

**4. REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary report on patentability. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the *PCT Applicant's Guide*.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed invention is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and mailing address of the IPEA/AU

AUSTRALIAN PATENT OFFICE  
PO BOX 200, WODEN ACT 2606, AUSTRALIA  
E-mail address: pct@ipaustalia.gov.au  
Facsimile No. (02) 6285 3929

Authorized officer

JENNIFER FERNANCE  
Telephone No. (02) 6283 2269

BEST AVAILABLE COPY

**PATENT COOPERATION TREATY**  
**PCT**  
**INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY**  
(Chapter II of the Patent Cooperation Treaty)  
(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 12565110/VPA/DJH/cmb	<b>FOR FURTHER ACTION</b>	See Form PCT/IPEA/416
International application No. <b>PCT/AU2005/000187</b>	International filing date (day/month/year) 14 February 2005	Priority date (day/month/year) 12 February 2004
International Patent Classification (IPC) or national classification and IPC  Int. Cl.  <i>C12N 1/20</i> (2006.01) <i>A61K 39/112</i> (2006.01) <i>A61P 37/04</i> (2006.01)		
Applicant  THE UNIVERSITY OF QUEENSLAND et al		

1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36. 2. This REPORT consists of a total of 5 sheets, including this cover sheet. 3. This report is also accompanied by ANNEXES, comprising: a. <input checked="" type="checkbox"/> (sent to the applicant and to the International Bureau) a total of 4 sheets, as follows: <div style="margin-left: 20px;"> <input type="checkbox"/> sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).  <input type="checkbox"/> sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.  b. <input type="checkbox"/> (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)) , containing a sequence listing and/or table related thereto, in electronic form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions). </div> 4. This report contains indications relating to the following items: <div style="margin-left: 20px;"> <input checked="" type="checkbox"/> Box No. I      Basis of the report  <input type="checkbox"/> Box No. II      Priority  <input type="checkbox"/> Box No. III      Non-establishment of opinion with regard to novelty, inventive step and industrial applicability  <input type="checkbox"/> Box No. IV      Lack of unity of invention  <input checked="" type="checkbox"/> Box No. V      Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement  <input type="checkbox"/> Box No. VI      Certain documents cited  <input type="checkbox"/> Box No. VII      Certain defects in the international application  <input checked="" type="checkbox"/> Box No. VIII      Certain observations on the international application </div>	
---	--

Date of submission of the demand 12 December 2005	Date of completion of this report 01 June 2006
Name and mailing address of the IPEA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaaustralia.gov.au Facsimile No. (02) 6285 3929	Authorized Officer  <b>JENNIFER FERNANCE</b> Telephone No. (02) 6283 2269

**BEST AVAILABLE COPY**

## Box No. 1 Basis of the report

## 1. With regard to the language, this report is based on:

- ☒ The international application in the language in which it was filed
- ☐ A translation of the international application into \_\_\_\_\_, which is the language of a translation furnished for the purposes of:
- ☐ international search (under Rules 12.3(a) and 23.1 (b))
- ☐ publication of the international application (under Rule 12.4(a))
- ☐ international preliminary examination (Rules 55.2(a) and/or 55.3(a))

2. With regard to the elements of the international application, this report is based on (*replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report*):

- ☐ the international application as originally filed/furnished
- ☒ the description:

pages 1-156 as originally filed/furnished

pages\* received by this Authority on \_\_\_\_\_ with the letter of

pages\* received by this Authority on \_\_\_\_\_ with the letter of

- ☒ the claims:

pages as originally filed/furnished

pages\* as amended (together with any statement) under Article 19

pages 157-160 received by this Authority on 13 December 2005 with the letter of 12 December 2005

pages\* received by this Authority on \_\_\_\_\_ with the letter of

- ☒ the drawings:

pages 1/32-32/32 as originally filed/furnished

pages\* received by this Authority on \_\_\_\_\_ with the letter of

pages\* received by this Authority on \_\_\_\_\_ with the letter of

- ☐ a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing.

3. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages
- ☐ the claims, Nos.
- ☐ the drawings, sheets/figs
- ☐ the sequence listing (*specify*):
- ☐ any table(s) related to the sequence listing (*specify*):

4. ☐ This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).

- ☐ the description, pages
- ☐ the claims, Nos.
- ☐ the drawings, sheets/figs
- ☐ the sequence listing (*specify*):
- ☐ any table(s) related to the sequence listing (*specify*):

\* If item 4 applies, some or all of those sheets may be marked "superseded."

BEST AVAILABLE COPY

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

## 1. Statement

Novelty (N)	Claims 6, 8, 9, 17, 21 and 23	YES
	Claims 1-5, 7, 10-16, 18-20, 22 and 24-27	NO
Inventive step (IS)	Claims 17	YES
	Claims 1-16, 18-27	NO
Industrial applicability (IA)	Claims 1-27	YES
	Claims -	NO

## 2. Citations and explanations (Rule 70.7)

The following documents identified in the International Search Report have been considered for the purposes of this report:

D2: US 6136325      D3: Bjorkman et al

New Citation

D5: Linde K et al (1998) Vet Micro Vol 62 pages 121-134 "Bacterial live vaccines with graded level of attenuation achieved by antibiotic resistance mutations: transduction experiments on the functional unit of resistance, attenuation and further accompanying markers".

Novelty Claims 1-5, 7, 10-16, 18-20, 22 and 24-27

Claims 1-23, 25 and 26 are directed the bacteria *per se*. The limitation that the agent has specific invasive or protective activities does not limit the use of the bacteria in methods using those activities. Therefore a citation that discloses bacteria having the defined mutations as presently described and/or defined would inherently have the defined attributes.

D3 discloses spontaneous rifampicin (Rif), streptomycin (Stm) or nalidixic acid (Nal) resistant *S typhimurium* mutants (page 123) that may or may not have other identifiable characteristics. It discloses that spontaneous mutants resistant to Rif or Nal in *Salmonella spp* has been mapped to the *rpoB* gene and *gyrA* genes, respectively. The use of these strains in vaccines is clearly envisaged (Abstract, Introduction and Discussion).

D5 discloses live attenuated bacteria produced from metabolic drift mutants prepared from both wild type bacteria (donor) and transduced bacteria (pages 123). They comprise those having Rif or Nal resistance and were found to be attenuated (Tables 2 and 5). They are extracted from faecal samples (page 126) and have a mutation in the Rif or Nal genes. The disclosed bacteria are those presently described and defined and therefore are considered to be able to infect stock animals and to colonise and invade the organs as presently defined.

D2 discloses attenuated *Salmonella spp* having Rif and Nal resistance and their use in vaccinating livestock, chickens and cattle (col 7, 9). The markers discussed by the Applicant are the resistance genes themselves. The attenuated bacteria are prepared by the selection of metabolic drift mutants resistant to Rif and/or Nal prepared from both mutated and wild type bacteria (see Examples and Figures). The mutants may or may not have another marker. However, the present claims do not exclude other metabolic drift markers.

(Continued in Supplemental Box)

RECT AVAILABLE COPY

**Box No. VIII** Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

The claims are not supported by the description. There is no support for:

- The disclosed bacteria having a reduced capacity to grow and replicate in the presence of bile acids;
- any attenuated bacteria having the required growth characteristics as having the required immunological activity;
- any attenuated bacteria having Rif or Nal resistance having the required growth characteristics and immunological activity;
- any double mutation having the required growth characteristics as providing the required immunological activity (the Examples disclose that specific double mutations are lethal in 50% of cases (RNM29) or are toxic when administered (RNM 4));
- the use of the attenuated bacteria as a carrier for an introduced antigen;
- the vaccination of a human.

BEST AVAILABLE COPY

## Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of: Box V

Each of the citations and the present specification discloses the use of growth media without the addition of bile acids to determine the growth rate of the bacteria. Each discloses a retarded growth pattern compared to the wild-type. Therefore it is considered that the disclosed bacteria would have a reduced capacity to grow and replicate in the presence of bile acids. Due to the species, natural modification and the attenuated bacteria disclosed in the citations, it is considered that they penetrate and colonise the defined organs as presently defined. The Skilled Addressee would appreciate that the form of the culture is immaterial to the working of the invention. The identification of the type of response elicited by a formulation does not confirm novelty on known formulation or known methods. Therefore claims 1-5, 7, 10-16, 18-20, 22 and 24-27 lack novelty in light of D2, D3 and D5.

Claims 6, 8, 9, 17, 21, 23 meet the criteria set forth in PCT Article 33(2) for novelty. The prior art published before the priority date does not disclose *Salmonella dublin* or the use of the define agent as a carrier for an introduced antigen. Therefore the subject matter of these claims is new and meets the requirements of Article 33(2) PCT with regard to novelty.

Inventive Step Claims 1-27

Claims 1-5, 7, 10-14, 16, 18-20, 22, 24-27 as for novelty.

In absence to the contrary, the teachings of D2, D3 or D5 is applicable to other strains of *Salmonella* including *S. dublin*. Therefore claims 6, 8, 9, 14, 22, 21 and 23 lack inventive step.

Industrial Applicability (IA) Claims 1-27

The invention defined in the claims is considered to meet the requirements of Industrial Applicability under Article 33(4) of the PCT because it can be made by, or used in, industry 6, 8, 9, 17, 21 and 23.

BEST AVAILABLE COPY